Laboratories

Hematology and Oncology

KEYWORDS

  • Leukemia
  • Malignant lymphoma
  • Molecular abnormalities
  • Molecular stratification
  • Drug resistance
  • Clonal evolution
  • Cancer immunology
  • CAR-T therapy
  • PDX model  

HEAD

KIYOI Hitoshi

Professor

Researchers

LAB MEMBER

Faculty Position Researchers
TERAKURA Seitaro Lecturer Researchers
ISHIKAWA Yuichi Lecturer Researchers
SHIMADA Kazuyuki Lecturer Researchers
USHIJIMA Yoko Lecturer of hospital Researchers
HANAJIRI Ryo Assistant Professor Researchers
FURUKAWA Katsuya Assistant Professor of hospital Researchers

CONTACT

Email med◎t.mail.nagoya-u.ac.jp(Please send a message after replacing "◎" mark with "@" mark. )
HP Private Page

OUTLINE

Hematopoietic organs (bone marrow), blood vessels, blood, spleen, thymus, lymph nodes and other tissues form an extremely close network in the body, and play important roles in keeping vital activities. Blood is simple to collect and easy to handle in test tubes, and thus has been used as a subject for research since old times. In the Hematology and Oncology department, we are working intensely on our mission to elucidate the pathological conditions of patients and to develop and establish novel treatments for patients by using various techniques from fields such as cell biology, biochemistry, genetic engineering, molecular biology and drug development.
The department has achieved results in a wide range of advanced research fields, including analysis of molecular mechanisms related to the onset of leukemia and malignant lymphoma, development of novel molecular targeted therapies, overcoming drug resistance to molecularly targeted drugs, and transplant immunology to improve results in hematopoietic stem cell transplantation.
The department got its start when the hematology group of the former First Department of Internal Medicine became independent. The former First Department of Internal Medicine was established in the Taisho Era (1912-1926), with Professor Seizo Katsunuma, known as the founder of the Japanese Society of Hematology, serving as the first professor. He was succeeded by Prof. Susumu Hibino, Prof. Itsuro Sobue, Prof. Hidehiko Saito and Prof. Tomoki Naoe, and the department developed with a history and tradition not only in hematology, but in internal medicine.
In the university hospital, we are in charge of the hematology ward, working to treat hematological malignancies (e.g., leukemia, lymphoma, myeloma), hematopoietic disorders (e.g., aplastic anemia), coagulation disorders (hemophilia, von Willebrand disease, etc.), and other diseases. The department currently has 23 graduate students in the doctoral course. Many people study overseas after graduating from the program; currently 3 members are studying in the United States, 1 member are studying in Canada. Of the 41 members, 7 have studied in other countries.

RESEARCH PROJECTS

The Department of Hematology and Oncology works closely with domestic and overseas laboratories to actively advance research in the following main areas.

(1) Clinical research group (Prof. Kiyoi, Prof. Hayakawa, Lecturer Terakura, Lecturer Ishikawa, Lecturer. Shimada, Hospital Lecturer. Ushijima, Assistant Prof. Hanajiri, Assistant Prof. Furukawa, Assistant Prof. Sato)
This clinical research group actively participates multi-center clinical trials to develop new treatment for hematological malignancies. We are a member of Japan Adult Leukemia Study Group (JALSG) and the Japan Clinical Oncology Group (JCOG). And we also conduct multicenter research as a member of the Nagoya Blood and Marrow Transplantation Group (NBMTG), and nationwide retrospective studies in the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

(2) Analyzing molecular pathogenesis/target therapy development group (Prof. Kiyoi, Lecturer Ishikawa, Lecturer. Shimada, Hospital Lecturer. Ushijima, Assistant Prof. Furukawa)
We investigate molecular pathology of hematological malignancies such as acute leukemia, myelodysplastic syndrome, and malignant lymphoma and develop novel therapies for them. We search for molecular targets for anti-cancer therapy through comprehensive gene analyses by next generation sequencer and analyses of patient-derived xenograft (PDX) that was established by transplanting patient tumor cells into mice. We also work together with pharmaceutical companies in the preclinical development of molecularly targeted drugs.

(3) Immunotherapy development group (Lecturer Terakura, Assistant Prof. Hanajiri)
Basic research in this group is focused on overcoming post-transplantation complications such as GVHD and viral infections, increasing the GVL effect, and developing of gene therapy using chimeric antigen receptor. We also aim to develop novel transplantation and immunotherapy through clinical research on “intra-bone marrow transplantation of cord blood” “application of MSC for transplantation” and “viral-specific CTL therapy”.

(4) Thrombosis and Hemostasis group (Blood Transfusion Dept.: Lecturer. Suzuki, Assistant Prof. Kanematsu, Assistant Prof. Okamoto)
This group studies the mechanisms of congenital and acquired bleeding disorders and thrombotic factors. We also develop and analyze original murine models which mimic human disorders, von Willebrand disease, MYH9 disorders and prothrombin disorders etc.

BIBLIOGRAPHY

2025
  1. Kuwano S, Terakura S, Imai K, Hirano S, Yokota H, Takeuchi Y, Sato T, Hanajiri R, Sawa M, Inagaki Y, Sakai T, Kurahashi S, Nishida T, Ozawa Y, Imahashi N, Ueki T, Murata M, Kiyoi H. Adjustment of low-dose ATG exposure improves outcomes in allogeneic hematopoietic stem cell transplantation: a prospective multicenter study. Cytotherapy. 2025 May 23:S1465-3249(25)00719-4.
  2. Hanajiri R, Wakabayashi H, Ishigiwa K, Ohara F, Hirano S, Yokota H, Kuwano S, Furukawa K, Shimada K, Sato T, Terakura S, Kiyoi H. Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion. Br J Haematol. 2025 Jul;207(1):180-188.
  3. Noura M, Yasuda T, Kiyoi H, Hayakawa F. Induction of T-Cell Differentiation by KLF4 in T-Cell Acute Lymphoblastic Leukemia Cells Harboring Activating Mutation in NOTCH3. FASEB J. 2025 May 31;39(10):e70613.
  4. Osaki M, Terakura S, Hirano S, Iwasa T, Hatanaka KC, Hatanaka Y, Sunagawa M, Kokuryo T, Adachi Y, Takeuchi Y, Hanajiri R, Sakanaka C, Murata M, Ebata T, Kiyoi H. Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells. J Immunother Cancer. 2025 May 7;13(5):e009825.
  5. Wakabayashi H, Terakura S, Ishigiwa K, Ohara F, Hirano S, Yokota H, Kuwano S, Furukawa K, Shimada K, Sato T, Hanajiri R, Kiyoi H. Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever. Int J Hematol. 2025 Jul;122(1):106-116.
  6. Shimada K, Yamaguchi M, Kuwatsuka Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto A, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Meguro A, Kin Y, Minami Y, Hashimoto D, Nishiyama T, Shimada S, Masaki Y, Okamoto M, Atsuta Y, Kiyoi H, Suzuki R, Nakamura S, Kinoshita T. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025 Jan 31; 80: 103078.
  7. Nishiwaki S, Terakura S, Morishita T, Goto T, Inagaki Y, Miyao K, Fukushima N, Hirano D, Tange N, Kurahashi S, Kuwatsuka Y, Kasai M, Iida H, Ozeki K, Sawa M, Nishida T, Kiyoi H. Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance. Int J Hematol. 2025 Apr;121(4):494-503.
  8. Sato T, Sugiyama D, Koseki J, Kojima Y, Hattori S, Sone K, Nishinakamura H, Ishikawa T, Ishikawa Y, Kato T, Kiyoi H, Nishikawa H. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages. JCI Insight. 2025 Jan 9;10(1):e178146.
  9. Adachi Y, Terakura S, Osaki M, Okuno Y, Sato Y, Sagou K, Takeuchi Y, Yokota H, Imai K, Steinberger P, Leitner J, Hanajiri R, Murata M, Kiyoi H. Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway. Nat Commun. 2024 Dec 10;15(1):10376.
  10. Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O. Cancer Sci. 2025 Feb;116(2):453-461.
  11. Takai M, Shimada K, Furukawa K, Yamaga Y, Yoshiyama S, Kagaya Y, Suzuki T, Hayashi K, Shimada S, Karube K, Kiyoi H. Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma. Cancer Sci. 2025 Jan;116(1):214-225.
2024
  1. Ishikawa Y, Ushijima Y, Kiyoi H. Recent advances in AML with mutated NPM1. Int J Hematol. 2024 ;120(5):556-565.
  2. Ushijima Y, Naruse S, Ishikawa Y, Kawashima N, Sanada M, Nakashima M, Kim JH, Terakura S, Kihara R, Watamoto K, Nishiyama T, Kitamura K, Matsushita T, Kiyoi H. Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia. Sci Rep. 2024 Jul 10;14(1):15906.
  3. Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y. Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. Blood Adv. 2024 ;8 : 5237-5247.
  4. Noura M, Tomita S, Yasuda T, Tsuzuki S, Kiyoi H, Hayakawa F. NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation. Cancer Med. 2024 Jul;13(13):e7445.
  5. Yano H, Koga K, Sato T, Shinohara T, Iriguchi S, Matsuda A, Nakazono K, Shioiri M, Miyake Y, Kassai Y, Kiyoi H, Kaneko S. Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model. Cell Stem Cell. 2024 Jun 6;31(6):795-802.e6.
  6. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. Am J Hematol. 2024 99(5):806-815.
  7. Sagou K, Sato Y, Okuno Y, Watanabe T, Inagaki T, Motooka Y, Toyokuni S, Murata T, Kiyoi H, Kimura H. Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation. PLoS Pathog. 2024 Feb 1; 20(2): e1011954.
  8. Noura M, Matsuo H, Yasuda T, Tsuzuki S, Kiyoi H, Hayakawa F. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia. Oncogene. 2024; 43: 447-456.
  9. Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). Int J Hematol. 2024; 119: 130-145.
  10. Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). Int J Hematol. 2024 Jan;119(1):24-38.
  11. Imai K, Takeuchi Y, Terakura S, Okuno S, Adachi Y, Osaki M, Umemura K, Hanajiri R, Shimada K, Murata M, Kiyoi H. Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models. Mol Cancer Ther. 2024; 23: 381-393.
2023
  1. Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, Fujiwara H, Nishida T, Hayashi M, Tanaka M, Kawakita T, Ikegame K, Katayama Y, Ara T, Ichinohe T, Kiyoi H, Matsuo K, Atsuta Y. Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades. Transplant Cell Ther. 2023: S2666-6367(23)01551-8.
  2. Takagi E, Terakura S, Fujigaki H, Okamoto A, Miyao K, Sawa M, Morishita T, Goto T, Ozawa Y, Nishida T, Fukushima N, Ozeki K, Hanajiri R, Saito K, Murata M, Tomita A, Kiyoi H. Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts. Int J Hematol. 2023; 118: 462-471.
  3. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y. High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. Hemasphere. 2023; 7: e899.
  4. Nishiwaki S, Sugiura I, Sato T, Kobayashi M, Osaki M, Sawa M, Adachi Y, Okabe M, Saito S, Morishita T, Kohno A, Nishiyama T, Iida H, Kurahashi S, Kuwatsuka Y, Sugiyama D, Ito S, Nishikawa H, Kiyoi H. Autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia is safe but poses challenges for long-term maintenance of molecular remission: Results of the Auto-Ph17 study. EJHaem. 2023; 4: 358-369.
  5. Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Lancet Haematol. 2023; 10: e419-e432.
  6. Kojima Y, Kawashima F, Yasuda T, Odaira K, Inagaki Y, Yamada C, Muraki A, Noura M, Okamoto S, Tamura S, Iwamoto E, Sanada M, Matsumura I, Miyazaki Y, Kojima T, Kiyoi H, Tsuzuki S, Hayakawa F. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity. Int J Hematol. 2023; 118: 65-74.
  7. Sahashi S, Shimada K, Takagi Y, Aoki T, Kunou S, Sakamoto A, Murase A, Furukawa K, Kagaya Y, Yamaga Y, Takai M, Tokuyama K, Shimada S, Nakamura S, Kiyoi H. Clinicopathological characteristics associated with the engraftment of patient lymphoma cells in NOG mice. Int J Hematol. 2023; 118: 221-230. doi: 10.1007/s12185-023-03604-z. 2.1
  8. Suzuki N, Suzuki N, Kawaguchi Y, Okamoto S, Kanematsu T, Katsumi A, Suzuki A, Tamura S, Kojima T, Kiyoi H, Matsushita T. The usefulness of tranexamic acid for bleeding symptoms of chronic consumptive coagulopathy complicated by aortic disease: a single-institute, retrospective study of 14 patients. Thromb J. 2023; 21:10.
  9. Odaira K, Yasuda T, Okada K, Shimooka T, Kojima Y, Noura M, Tamura S, Kurahashi S, Iwamoto E, Sanada M, Matsumura I, Miyazaki Y, Kojima T, Kiyoi H, Tsuzuki S, Hayakawa F. Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene. Cancer Sci. 2023; 114: 781-792.
  10. Tsuzuki S, Yasuda T, Goto H, Maeda N, Akahane K, Inukai T, Yamamoto H, Karnan S, Ota A, Hyodo T, Konishi H, Hosokawa Y, Kiyoi H, Hayakawa F. BCL6 inhibition ameliorates ruxolitinib resistance in CRLF2-rearranged acute lymphoblastic leukemia. Haematologica. 2023; 108: 394-408.
2022
  1. Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. Int J Hematol. 2022; 116: 228-238.
  2. Okamoto S, Tamura S, Sanda N, Odaira K, Hayakawa Y, Mukaide M, Suzuki A, Kanematsu T, Hayakawa F, Katsumi A, Kiyoi H, Kojima T, Matsushita T, Suzuki N. VWF-Gly2752Ser, a novel non-cysteine substitution variant in the CK domain, exhibits severe secretory impairment by hampering C-terminal dimer formation. J Thromb Haemost. 2022; 20: 1784-1796.
  3. Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, Morita Y, Eto T, Katsuoka Y, Takezako N, Uoshima N, Imada K, Ando J, Komeno T, Mori A, Ishikawa Y, Satake A, Watanabe J, Kawakami Y, Morita T, Taneike I, Nakayama M, Duan Y, Garbayo Guijarro B, Delgado A, Llamas C, Kiyoi H. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. Int J Hematol. 2022; 116: 89-101.
  4. Dai YT, Zhang F, Fang H, Li JF, Lu G, Jiang L, Chen B, Mao DD, Liu YF, Wang J, Peng LJ, Feng C, Chen HF, Mu JX, Zhang QL, Wang H, Ariffin H, Moy TA, Wang JH, Lou YJ, Chen SN, Wang Q, Liu H, Shan Z, Matsumura I, Miyazaki Y, Yasuda T, Dou LP, Yan XJ, Yan JS, Yeoh AE, Wu DP, Kiyoi H, Hayakawa F, Jin J, Wang SY, Sun XJ, Mi JQ, Chen Z, Huang JY, Chen SJ. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. Proc Natl Acad Sci U S A. 2022; 119: e2120787119.
  5. Kawashima N, Ishikawa Y, Kim JH, Ushijima Y, Akashi A, Yamaguchi Y, Hattori H, Nakashima M, Ikeno S, Kihara R, Nishiyama T, Morishita T, Watamoto K, Ozawa Y, Kitamura K, Kiyoi H. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nat Commun. 2022; 13: 1624.
  6. Adachi Y, Sakai T, Terakura S, Shiina T, Suzuki S, Hamana H, Kishi H, Sasazuki T, Arase H, Hanajiri R, Goto T, Nishida T, Murata M, Kiyoi H. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. Int J Hematol. 2022; 115: 371-381.
2021
  1. Shimada K, Kiyoi H. Current progress and future perspectives of research on intravascular large B-cell lymphoma. Cancer Sci. 2021;112: 3953-3961.
  2. Okuno S, Adachi Y, Terakura S, Julamanee J, Sakai T, Umemura K, Miyao K, Goto T, Murase A, Shimada K, Nishida T, Murata M, Kiyoi H. Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. J Immunol. 2021; 206: 2862-2874.
  3. Kunou S, Shimada K, Takai M, Sakamoto A, Aoki T, Hikita T, Kagaya Y, Iwamoto E, Sanada M, Shimada S, Hayakawa F, Oneyama C, Kiyoi H. Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene. 2021; 40: 3989-4003.
  4. Julamanee J, Terakura S, Umemura K, Adachi Y, Miyao K, Okuno S, Takagi E, Sakai T, Koyama D, Goto T, Hanajiri R, Hudecek M, Steinberger P, Leitner J, Nishida T, Murata M, Kiyoi H. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Mol Ther. 2021; 29: 2677-2690.
  5. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, Hirakawa A, Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. Stem Cells Transl Med. 2021; 10: 542-553.
  6. Nishiwaki S, Sugiura I, Koyama D, Ozawa Y, Osaki M, Ishikawa Y, Kiyoi H. Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia. Biomark Res. 2021; 9: 13.
  7. Shimada K, Kenichi Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H. Frequent Genetic Alterations in Immune Checkpoint-Related Genes in Intravascular Large B-Cell Lymphoma. Blood 2021; 137: 1491-1502.
2020
  1. Nishiwaki S, Kim JH, Ito M, Maeda M, Okuno Y, Koyama D, Ozawa Y, Gunji M, Osaki M, Kitamura K, Ushijima Y, Ishikawa Y, Miyamura K, Sugiura I, Kiyoi H. Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated with Improved Prognosis but No Specific Molecular Features. Front Oncol. 2020; 10: 586567.
  2. Sakai T, Terakura S, Miyao K, Okuno S, Adachi Y, Umemura K, Julamanee J, Watanabe K, Hamana H, Kishi H, Leitner J, Steinberger P, Nishida T, Murata M, Kiyoi H. Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity. Mol Ther Oncolytics. 2020; 18: 613-622.
  3. Tange N, Hayakawa F, Yasuda T, Odaira K, Yamamoto H, Hirano D, Sakai T, Terakura S, Tsuzuki S, Kiyoi H. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells. Biomed Pharmacother. 2020 Aug; 128: 110330.
  4. Kawashima N, Ishikawa Y, Atsuta Y, Sawa M, Ozawa Y, Hayashi M, Kohno A, Tomita A, Maeda T, Sakaida E, Usuki K, Hagihara M, Kanamori H, Matsuoka H, Kobayashi M, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Allogeneic HSCT at the first remission for younger adults with FLT3-ITD AML: The JALSG AML209-FLT3-SCT Study. Cancer Sci. 2020; 111: 2472-2481.
  5. Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21: 593-602.
  6. Kiyoi H, Morris JD, Oh I, Maeda Y, Minami H, Miyamoto T, Sakura T, Iida H, Tuglus CA, Chen Y, Dos Santos C, Kalabus J, Anderson A, Hata T, Nakashima Y, Kobayashi Y. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Sci. 2020; 111: 1314-1323.
  7. Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020; 4: 66-75.
  8. Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020; 111 :312-322.

MESSAGE

Recruitment of students to the master’s and doctoral courses
In the Department of Hematology and Oncology, we aim to advance understanding of molecular pathology in blood disease, develop new diagnostic and treatment methods, and promote high quality clinical research that can be used in evidence-based medicine. The Department’s graduate students work intensely to produce original research findings to present to the world with the ultimate goal of enabling patients to regain their health. Each project is executed together with a project leader who possesses advanced research skills, and we have a system to provide consistent guidance from carrying out the research to publishing the results. We are recruiting graduate students who move these researches forward. People with interest in the master’s and doctoral courses in the Department of Hematology and Oncology are encouraged to contact us. Program tours are available as needed.

OPEN CAMPUS

Back to top of page